A Phase 2 interventional study of Trazodone 25 mg in Insomnia Chronic, Older People and Drug Therapy, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders — 4 open to participants now, 4 under way, none of them phase 3. Trazodone · Sleep Initiation and Maintenance Disorders.
Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2, and was the 10th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →4 of the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders are open now, in 2 countries. Recruiting first, the newest first:
University of Pennsylvania · Sites in United States
Ages 18–80
Brigham and Women's Hospital · Sites in United States
Ages 40–62 · Women only
Milton S. Hershey Medical Center · Sites in United States, Canada
Ages 18+
By country, each count listing its studies:
Trazodone: first FDA approval 1981 (DESYREL). What it is approved for, and how studies give it, is on its page →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 146 across the 12 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 2 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies testing trazodone in Sleep Initiation and Maintenance Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06983080Centre hospitalier de l'Université de Montréal (CHUM)Efficacy of Trazodone to Treat Insomnia in Older Adults (TRADITION Study) | 2027-07 |
| NCT06281756Milton S. Hershey Medical CenterCognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing trazodone in Sleep Initiation and Maintenance Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate how effective trazodone is in treating insomnia in adults aged 65 years and older. The main question it aims to answer is :
- Is trazodone more effective than a placebo in reducing the severity of insomnia symptoms in older adults?
Participants will :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 25 to 50 mg of trazodone once daily at bedtime for 28 days. After a 14-day washout period, participants will receive a placebo for another 28 days.
Drug: Trazodone 25 mg
Participants will receive a placebo once daily at bedtime for 28 days. After a 14-day washout period, participants will receive 25 to 50 mg of trazodone for another 28 days.
Drug: Trazodone 25 mg
Trazodone 25 mg at bedtime, which can be increased to 50 mg after 14 days of treatment.
Insomnia severity index
The ISI is a self-assessment questionnaire that evaluates the nature, severity, and impact of insomnia. The typical recall period is the past month. The dimensions assessed are: the severity of falling asleep, maintaining sleep, and waking up too early in the morning; sleep dissatisfaction; the interference of sleep difficulties with daytime functioning; the visibility of sleep problems to others; and the distress caused by sleep difficulties. A 5-point Likert scale is used to evaluate each item. The total score is interpreted as follows: no insomnia 0-7; subclinical insomnia 8-14; moderate insomnia 15-21; and severe insomnia 22-28. It is increasingly used as a measure of treatment response in clinical research. Data confirm its reliability and the validity of the measurements obtained in the older adult population.
Time frame: At baseline or at day 1, at day 36 and at day 77.
Insomnia daytime symptoms and Impacts Questionnaire
The IDSIQ is a questionnaire covering 14 different items that specifically measures the impact of insomnia on various aspects of daytime functioning. The questions are grouped into three areas, each representing the main daytime symptoms and impacts of insomnia on drowsiness (four items), alertness/cognition (six items), and mood (four items). Each item is rated on an 11-point numerical scale (from 0 to 10), with lower scores indicating better daytime functioning. It has been found to be sensitive to changes in patients experiencing daytime effects. It is quick to administer, easy to complete, and has reliable reproducibility (test-retest). It can be used in clinical trials to assess changes and the effectiveness of a treatment on daytime functioning and for the recording of new drugs for insomnia. Regulatory authorities now require that the effectiveness of clinical trials for medical products against insomnia be measured not only by treating physicians but also by the p
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Subjective Sleep onset latency
Subjective time duration, in minutes, between the time the participant attempts to fall asleep (e.g., lights off, lying in bed) and the time they perceive they have fallen asleep.
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Subjective wake after sleep onset
The perceived total duration, in minutes, of all periods of wakefulness occurring after initial sleep onset and before final awakening
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Subjective Total sleep time
The perceived total duration, in minutes, of actual sleep obtained during the night, excluding periods of wakefulness.
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Subjective sleep efficiency
The perceived percentage of time spent asleep while in bed, calculated as the ratio of subjective total sleep time (sTST) to time in bed (TIB), multiplied by 100
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Objective sleep onset latency
The estimated duration, in minutes, between the time the participant attempts to fall asleep (e.g., lights out or bedtime) and the onset of the first sustained period of sleep, as detected by actigraphy
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Objective Wake After Sleep Onset
The estimated total duration, in minutes, of wakefulness occurring after the initial sleep onset and before final awakening, as detected by actigraphy
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Objective Total Sleep Time
The estimated total duration, in minutes, of actual sleep obtained during the sleep period, as detected by actigraphy, excluding all periods of wakefulness
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Objective Sleep Efficiency
The estimated percentage of time spent asleep while in bed, calculated as the ratio of objective total sleep time (oTST) to objective time in bed (oTIB), multiplied by 100 as measured by actigraphy.
Time frame: At baseline daily from day 1 to day 7, and during 7 days the first and last week of each treatment
Adverse events
Incidence of at least one adverse event. Incidence of severe adverse events. Proportion of participants who discontinued due to adverse events.
Time frame: At Day 36 and day 77
Plan to share: No — There is no need since it is a single center study.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.
Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 20 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trazodone
Sleep Initiation and Maintenance Disorders →
Centre hospitalier de l'Université de Montréal (CHUM) →